With the advent of new targeted and cellular therapies, the treatment landscape for patients with chronic lymphocytic leukaemia (CLL) has considerably changed in the last years. Current CLL management is based on updated risk stratification strategies considering demography, fitness level, genetic aberrations, previous treatments, as well as disease relapse, in addition to the clinical stage. While the CLL treatment paradigm was changed in the last decade due to approval of novel targeted therapies, disease relapse rates are still high. Additional clinical trials are needed to answer outstanding questions or provide alternatives for further improvements of long-term efficacy and safety/tolerability in the overall CLL population and specifically in patients with high-risk CLL.
This article describes contemporary CLL management, with a focus on current and emerging therapies in first-line disease and subsequent settings. Results were published in the Journal for Clinical Studies in Feb 2020, pp 36-37.
